First Berlin Equity Research GmbH gives the company's share a 'buy' rating and sees the fair value of the share at €67.90.
Hennigsdorf, 9 September 2015 – With the publication of the first research report, First Berlin Equity Research GmbH is starting coverage of Deutsche Biotech Innovativ AG (“DBI”). First Berlin's initial assessment gives the company's share a 'buy' rating and sees the fair value of the share at €67.90.
As strengths of the company, First Berlin analyst Simon Scholes emphasises, inter alia, DBI's innovative development approach. As a starting point for the identification of new drug targets DBI uses the thorough analysis of the blood of diseased patients. Only afterwards a target-related drug is being developed. This differs strongly from the conventional approach, in which targets are identified in animals first, and by this raises the probability that a drug candidate proves to be efficacious in the human body at the end of the development process. First Berlin also takes a favourable view of the unique approach to treating sepsis with DBI's lead product, the drug Adrecizumab, and DBI's strategic patent portfolio, which protects DBI's sepsis drug development until at least 2032.
Pipeline with blockbuster potential
DBI's revenue potential particularly arises from the three current drug candidates that are in development in DBI's project companies. First Berlin's analyst sees the market potential of the sepsis drug Adrecizumab as being around €3.6 billion a year. The market potential of DB1RA, a drug for the prevention of breast cancer, is estimated at €1.7 billion a year and the drug AB2302 for the treatment of cancer could accordingly achieve revenues of €0.8 billion a year.
The complete research study is available on Deutsche Biotech Innovativ AG's website via the following link: http://www.dbi-ag.de/investoren-presse/aktie/#anchor_d0823b06_Research-Reports
Share split executed as planned
Following the resolution by the annual general meeting on 23 July 2015 to issue bonus shares, the company's share capital now, after the measure is completed, is €894,600.00, divided into 894,600 no-par value bearer shares. Thus, the price target of First Berlin relates to the fair value after share split.
About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG (“DBI”) is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. Its focus is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting in 2015.
The preclinical and clinical studies are mainly
carried out by project companies in which DBI AG holds a stake. Currently, DBI
AG holds 26% of AdrenoMed AG (Agent: Adrecizumab), 25% of Oncoprevent GmbH
(Agent: DB1RA), 100% of AngioBiomed GmbH (Agent: AB2302) and 50% of My Life
Diagnostics GmbH (Diagnostic agent for urinary tract infection).
DBI aims to further expand its drug pipeline and invest in the research and development of drugs that have high unique-selling-point potential.
Both members of DBI's Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialising in the identification of blood biomarkers for treating serious illnesses. It was sold in 2009 for around €330 million. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).
Deutsche Biotech Innovativ AG
Frau Susanne Wallace
Tel.: +49 (0)3302 20 77 811
Kirchhoff Consult AG
Frau Anja Ben Lekahl
Tel.: +49 (0)40 609 186 55